Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. In this multicentre phase I dose escalation study, 71 patients with refractory solid tumours w...

Descripción completa

Detalles Bibliográficos
Autores principales: Strumberg, D, Schultheis, B, Adamietz, I A, Christensen, O, Buechert, M, Kraetzschmar, J, Rajagopalan, P, Ludwig, M, Frost, A, Steinbild, S, Scheulen, M E, Mross, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584942/
https://www.ncbi.nlm.nih.gov/pubmed/19002179
http://dx.doi.org/10.1038/sj.bjc.6604724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584942/
https://www.ncbi.nlm.nih.gov/pubmed/19002179
http://dx.doi.org/10.1038/sj.bjc.6604724

Ejemplares similares